Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
PR Newswire•08/10/2026•08:00 ET
0
Key Highlights
- ➤EQUINOX-HFpEF doses first patient in Phase 2 HFpEF trial
- ➤Trial expects approximately 90 adults with symptomatic HFpEF
- ➤Participants receive 25 mg, 50 mg, or placebo for up to 12 weeks
- ➤EDG-15400 Phase 1 data and Phase 2 design set for HFSA 2026 presentations
Expert Statements
Kevin Koch, President and Chief Executive Officer of Edgewise Therapeutics
“Dosing the first patient in the EQUINOX-HFpEF trial marks an important milestone in evaluating EDG-15400's potential to improve the impaired cardiac relaxation that characterizes HFpEF”
Kevin Koch, President and Chief Executive Officer of Edgewise Therapeutics
“This study seeks to extend our cardiac sarcomere platform into an underserved patient population and will help determine whether this differentiated mechanism can benefit patients with symptomatic HFpEF.”
James L. Januzzi, Chair of the EQUINOX-HFpEF Executive Committee and the Hutter Family Professor of Medicine at Harvard Medical School
“HFpEF remains one of the most challenging forms of heart failure to treat, in part because current therapies do not directly address impaired cardiac relaxation”
James L. Januzzi, Chair of the EQUINOX-HFpEF Executive Committee and the Hutter Family Professor of Medicine at Harvard Medical School
“Based on preclinical observations, EDG-15400 may represent a more direct approach to HFpEF.”
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 PR Newswire
– Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% –
Get started
Create a free account to read the full story.